Synergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide CIC NDA and IBS-C Clinical Development Program

NEW YORK--(BUSINESS WIRE) July 15, 2016 --Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced it has reached the Food and Drug Administration (FDA) mid-cycle review milestone for the plecanatide new drug application (NDA) in chronic...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news